Cipher Pharmaceuticals Framtida tillväxt
Future kriterier kontrolleras 1/6
Cipher Pharmaceuticals förväntas öka intäkter och intäkter med 2.1% respektive 8.2% per år. EPS förväntas tillväxt med 0.8% per år. Avkastningen på eget kapital förväntas bli 14% om 3 år.
Viktig information
2.1%
Tillväxttakt i vinsten
0.76%
Tillväxttakt för EPS
| Pharmaceuticals vinsttillväxt | 31.0% |
| Intäkternas tillväxttakt | 8.2% |
| Framtida avkastning på eget kapital | 13.98% |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 12 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Analysartikel • May 14
Investors Shouldn't Be Too Comfortable With Cipher Pharmaceuticals' (TSE:CPH) Earnings
Cipher Pharmaceuticals Inc. ( TSE:CPH ) announced strong profits, but the stock was stagnant. Our analysis suggests...
Uppdatering av berättelse • May 08
CPH: Higher Cash Returns And Buybacks Will Support Future Upside
Analysts have lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E. These changes support a slightly higher fair value estimate.Uppdatering av berättelse • Apr 23
CPH: Higher Cash Flow Plans And Buybacks Will Support Future Upside
Analysts have nudged their fair value estimate for Cipher Pharmaceuticals to CA$21 from CA$20, tying the CA$1 price target change to updated assumptions around revenue growth, profit margins and a slightly higher discount rate alongside a lower future P/E. Analyst Commentary Recent research points to a modestly higher fair value for Cipher Pharmaceuticals, with bullish analysts lifting their price target to CA$21 from CA$20.
Uppdatering av berättelse • Apr 09
CPH: Fair Outlook Will Weigh Natroba Expansion And Acquisition Execution
Analysts have nudged their price target on Cipher Pharmaceuticals up to CA$21 from CA$20, citing updated assumptions that keep fair value broadly steady while fine tuning expectations around growth, margins, and P/E levels. Analyst Commentary The latest price target move to CA$21 from CA$20 signals only a modest reset in expectations, rather than a major shift in conviction.Uppdatering av berättelse • Mar 26
CPH: Balanced Outlook Will Weigh New Drug Review And Acquisition Execution
Analysts recently lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, reflecting updated assumptions that combine a higher revenue growth outlook with slightly lower profit margin and future P/E expectations. Analyst Commentary The latest price target move to CA$21 suggests that covering analysts are refining their assumptions rather than making a sweeping change in their outlook.Uppdatering av berättelse • Mar 12
CPH: New Drug Review Will Support Future Upside Potential
Analysts are maintaining their CA$18.60 price target on Cipher Pharmaceuticals. This reflects only small adjustments to their revenue growth and future P/E assumptions, rather than a change in their overall view of the stock.Uppdatering av berättelse • Feb 26
CPH: New Drug Review And Strong Margins Will Support Further Upside
Analysts kept their CA$18.60 price target on Cipher Pharmaceuticals unchanged, citing only small tweaks to their revenue growth, profit margin and future P/E assumptions that did not materially shift their view of the stock’s value. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad) for the treatment of head lice and scabies, moving the product into the formal review process (Key Developments).Uppdatering av berättelse • Feb 11
CPH: Higher Margins And New Submission Will Support Future Upside
Analysts have trimmed their price target on Cipher Pharmaceuticals to reflect a more muted revenue growth outlook of 4.30% and a slightly higher discount rate of 6.25%, while still acknowledging a stronger projected profit margin of 39.46% and a broadly similar future P/E of 17.63. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad), targeting head lice and scabies in the Canadian market (Key Developments).Uppdatering av berättelse • Jan 26
CPH: Share Repurchases Will Drive Future Earnings Power And Upside Potential
Analysts have modestly adjusted their price target for Cipher Pharmaceuticals to reflect slightly updated assumptions around revenue growth of 10.48%, profit margin of 32.39%, and a future P/E of 17.81x. The overall fair value estimate remains at $18.60.Uppdatering av berättelse • Jan 11
CPH: Share Repurchases Will Support Stronger Future Earnings Profile
Analysts have trimmed their price target on Cipher Pharmaceuticals by aligning slightly lower revenue growth and profit margin assumptions with a modestly higher future P/E. This keeps fair value around $18.60 and reflects a more measured outlook on the company’s earnings profile.Uppdatering av berättelse • Dec 27
CPH: Share Repurchases And Rising Margins Will Support Stronger Future Earnings
Cipher Pharmaceuticals' analyst price target has been raised from 14.50 dollars to 18.60 dollars, as analysts cite slightly stronger expected revenue growth, modestly higher profit margins, and a richer future earnings multiple as justification for the upward revision. What's in the News Cipher Pharmaceuticals completed the latest tranche of its share repurchase program between July 1, 2025 and September 30, 2025, buying back 141,700 shares, or 0.56 percent of its float, for CAD 2.18 million (Key Developments) Under the buyback announced on May 1, 2025, the company has now repurchased a total of 371,978 shares, representing 1.46 percent of shares outstanding, for aggregate consideration of CAD 5.12 million (Key Developments) Valuation Changes The consensus analyst price target has risen significantly from 14.50 dollars to 18.60 dollars, reflecting a materially higher fair value assessment.Uppdatering av berättelse • Dec 12
CPH: Share Buybacks Will Support Earnings And Maintain A Balanced Outlook
Analysts have nudged their price target on Cipher Pharmaceuticals higher, from 14.00 dollars to 14.50 dollars, citing stronger expected revenue growth, improved profit margins, and a more attractive forward earnings multiple despite a slightly higher discount rate. What's in the News Cipher Pharmaceuticals repurchased 141,700 shares between July 1 and September 30, 2025, totaling CAD 2.18 million and representing 0.56% of outstanding shares (company buyback update).Analysartikel • Nov 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...Analysartikel • Oct 10
These 4 Measures Indicate That Cipher Pharmaceuticals (TSE:CPH) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Uppdatering av berättelse • Sep 05
Expansion Into Canada Will Shape Global Dermatology Success
Cipher Pharmaceuticals' future P/E has risen sharply, indicating increased valuation relative to earnings, while the net profit margin is stable, resulting in no change to the consensus analyst price target at CA$17.90. What's in the News Cipher Pharmaceuticals is actively seeking accretive acquisitions and in-licensing opportunities, with a strategic focus on complementary U.S.-based assets and companies.Analysartikel • Aug 29
Cipher Pharmaceuticals Inc.'s (TSE:CPH) Shares Climb 27% But Its Business Is Yet to Catch Up
The Cipher Pharmaceuticals Inc. ( TSE:CPH ) share price has done very well over the last month, posting an excellent...Analysartikel • May 16
We Think That There Are More Issues For Cipher Pharmaceuticals (TSE:CPH) Than Just Sluggish Earnings
Investors weren't pleased with the recent soft earnings report from Cipher Pharmaceuticals Inc. ( TSE:CPH ). Our...Analysartikel • May 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have had a really impressive month, gaining 29% after a shaky period...Analysartikel • Apr 28
Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Ny berättelse • Feb 23
Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence
Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.Analysartikel • Dec 13
We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Nov 14
Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think
Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) earnings announcement last week contained some soft numbers, disappointing...Analysartikel • Nov 12
With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders won't be pleased to see that the share price has had a very rough...Analysartikel • Nov 09
Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...Analysartikel • Mar 23
There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have continued their recent momentum with a 26% gain in the last month...Analysartikel • Mar 22
Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
The market rallied behind Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) stock, leading do a rise in the share price after...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 65 | 27 | N/A | 40 | 2 |
| 12/31/2027 | 62 | 26 | N/A | 39 | 3 |
| 12/31/2026 | 53 | 22 | 30 | 28 | 4 |
| 3/31/2026 | 51 | 31 | 29 | 30 | N/A |
| 12/31/2025 | 50 | 27 | 30 | 30 | N/A |
| 9/30/2025 | 50 | 17 | 30 | 30 | N/A |
| 6/30/2025 | 48 | 12 | -59 | 21 | N/A |
| 3/31/2025 | 40 | 9 | -59 | 21 | N/A |
| 12/31/2024 | 33 | 12 | -60 | 20 | N/A |
| 9/30/2024 | 26 | 16 | -67 | 13 | N/A |
| 6/30/2024 | 22 | 23 | 17 | 17 | N/A |
| 3/31/2024 | 22 | 23 | 14 | 14 | N/A |
| 12/31/2023 | 21 | 20 | 16 | 16 | N/A |
| 9/30/2023 | 21 | 32 | 15 | 15 | N/A |
| 6/30/2023 | 20 | 28 | 13 | 13 | N/A |
| 3/31/2023 | 20 | 27 | 13 | 13 | N/A |
| 12/31/2022 | 21 | 27 | 11 | 11 | N/A |
| 9/30/2022 | 22 | 10 | 15 | 15 | N/A |
| 6/30/2022 | 21 | 8 | 11 | 11 | N/A |
| 3/31/2022 | 22 | 9 | 11 | 11 | N/A |
| 12/31/2021 | 22 | 8 | 14 | 14 | N/A |
| 9/30/2021 | 22 | 5 | 14 | 14 | N/A |
| 6/30/2021 | 23 | 6 | 12 | 12 | N/A |
| 3/31/2021 | 21 | 3 | 11 | 11 | N/A |
| 12/31/2020 | 22 | 4 | 11 | 12 | N/A |
| 9/30/2020 | 21 | 7 | 7 | 7 | N/A |
| 6/30/2020 | 22 | 3 | 10 | 11 | N/A |
| 3/31/2020 | 23 | 4 | 11 | 12 | N/A |
| 12/31/2019 | 22 | 3 | N/A | 8 | N/A |
| 9/30/2019 | 23 | -1 | N/A | 8 | N/A |
| 6/30/2019 | 22 | 2 | N/A | 6 | N/A |
| 3/31/2019 | 23 | 3 | N/A | 2 | N/A |
| 12/31/2018 | 23 | 1 | N/A | 8 | N/A |
| 9/30/2018 | 28 | 6 | N/A | 13 | N/A |
| 6/30/2018 | 34 | 9 | N/A | 18 | N/A |
| 3/31/2018 | 37 | 11 | N/A | 19 | N/A |
| 12/31/2017 | 40 | 11 | N/A | 13 | N/A |
| 9/30/2017 | 34 | 7 | N/A | 11 | N/A |
| 6/30/2017 | 32 | 5 | N/A | 9 | N/A |
| 3/31/2017 | 31 | 1 | N/A | 10 | N/A |
| 12/31/2016 | 30 | 4 | N/A | 11 | N/A |
| 9/30/2016 | 33 | 6 | N/A | 8 | N/A |
| 6/30/2016 | 34 | 2 | N/A | 7 | N/A |
| 3/31/2016 | 34 | 1 | N/A | 7 | N/A |
| 12/31/2015 | 34 | 2 | N/A | 8 | N/A |
| 9/30/2015 | 32 | 3 | N/A | 12 | N/A |
| 6/30/2015 | 30 | 13 | N/A | 16 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: CPH s prognostiserade vinsttillväxt ( 2.1% per år) ligger under sparkvoten ( 3% ).
Resultat vs marknad: CPH s intäkter ( 2.1% per år) förväntas växa långsammare än marknaden för Canadian ( 10.7% per år).
Höga tillväxtresultat: CPH s intäkter förväntas växa, men inte avsevärt.
Intäkt vs marknad: CPH s intäkter ( 8.2% per år) förväntas växa snabbare än Canadian marknaden ( 4.5% per år).
Hög tillväxtintäkter: CPH s intäkter ( 8.2% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: CPH s avkastning på eget kapital förväntas bli låg om 3 år ( 14 %).
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/20 12:47 |
| Aktiekurs vid dagens slut | 2026/05/20 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Cipher Pharmaceuticals Inc. bevakas av 8 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| David Novak | ATB Cormark Historical (Cormark Securities) |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |